Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 10, 2013 09:00 ET | Source: Arch Therapeutics, Inc.

Arch Therapeutics Co-Founder Dr. Ellis-Behnke to Speak at Nanomanufacturing Summit 2013 in Philadelphia, October 15, 2013

WELLESLEY, MA--(Marketwired - Oct 10, 2013) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), is pleased to announce that co-founding and inventing scientist, Dr. Rutledge...
October 07, 2013 09:00 ET | Source: Arch Therapeutics, Inc.

Arch Therapeutics Announces Approval of $1 Million Massachusetts Life Sciences Center Accelerator Loan

WELLESLEY, MA--(Marketwired - Oct 7, 2013) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a life sciences company and developer of AC5™, a novel product aimed at...
September 20, 2013 09:00 ET | Source: Arch Therapeutics, Inc.

Arch Therapeutics Announces Participation at the 2013 Boulder Peptide Symposium in Colorado September 25-27

CAMBRIDGE, MA--(Marketwired - Sep 20, 2013) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), today announced it will be featured as a presenting company at the Boulder Peptide...
September 03, 2013 09:00 ET | Source: Arch Therapeutics, Inc.

Arch Therapeutics Announces Participation at the 15th Annual Rodman & Renshaw Global Investment Conference in New York City September 8-10th

CAMBRIDGE, MA--(Marketwired - Sep 3, 2013) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), today announced it will be featured as a presenting company at the 15th Annual Rodman...
August 06, 2013 15:05 ET | Source: Arch Therapeutics, Inc.

Arch Therapeutics Announces Plans for Upcoming Activities

CAMBRIDGE, MA--(Marketwired - Aug 6, 2013) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a life science company and developer of AC5™, a novel product aimed at...
July 30, 2013 09:00 ET | Source: Arch Therapeutics, Inc.

Arch Therapeutics Reports on Current Activities

CAMBRIDGE, MA--(Marketwired - Jul 30, 2013) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a life science company and developer of AC5™, a novel product aimed at...
July 23, 2013 09:50 ET | Source: Arch Therapeutics, Inc.

Arch Therapeutics Co-Founder Dr. Ellis-Behnke Speaks at 6th Annual CLINAM Nanomedicine Summit in Basel, Switzerland

CAMBRIDGE, MA--(Marketwired - Jul 23, 2013) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a life science company and developer of AC5™, a novel product aimed at...
July 16, 2013 09:00 ET | Source: Arch Therapeutics, Inc.

Arch Therapeutics Co-Founder Rutledge Ellis-Behnke Delivers Keynote at Nanomaterials Technology Transfer Conference in Corfu, Greece

CAMBRIDGE, MA--(Marketwired - Jul 16, 2013) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a life science company and developer of AC5™, a novel product aimed at...
July 08, 2013 09:00 ET | Source: Arch Therapeutics, Inc.

Arch Therapeutics Appoints Senior Management Team Members

CAMBRIDGE, MA--(Marketwired - Jul 8, 2013) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a life science company and developer of AC5™, a novel product aimed at...
July 02, 2013 09:00 ET | Source: Arch Therapeutics, Inc.

Arch Therapeutics Introduces Experienced Directors and Executive Leadership

CAMBRIDGE, MA--(Marketwired - Jul 2, 2013) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a life science company and developer of AC5™, a novel product aimed at...